Table 2. mHSPC metastatic burden and oncological outcome.
| Variable | Total (n=122) | ADT+abiraterone (n=102) | ADT+docetaxel (n=20) | p-value | |
|---|---|---|---|---|---|
| Regional LNM | 85 (69.7) | 69 (67.6) | 16 (80.0) | 0.272 | |
| Other LNM (M1a) | 53 (43.4) | 44 (43.1) | 9 (45.0) | 0.878 | |
| Bone Metastasis (M1b) | 109 (89.3) | 91 (89.2) | 19 (90.0) | 0.917 | |
| Visceral metastasis (M1c) | 31 (25.4) | 26 (25.5) | 5 (25.0) | 0.963 | |
| Extent of metastasis | 0.726 | ||||
| Low volume | 106 (86.9) | 89 (87.3) | 17 (85.0) | ||
| High volume | 16 (13.1) | 13 (12.7) | 3 (15.0) | ||
| PSA at treatment start (ng/mL) | 180.0 (65.6–610.5) | 185.3 (65.6–638.2) | 100.0 (52.3–578.5) | 0.398 | |
| Testosterone at treatment start (ng/mL) | 3.7 (2.8–4.8) | 4.1 (3.1–5.3) | 3.1 (2.7–4.6) | 0.452 | |
| PSA nadir (ng/mL) | 0.3 (0.0–2.3) | 0.1 (0.0–2.3) | 0.7 (0.6–2.4) | 0.085 | |
| PSA nadir duration (mo) | 5.4 (2.9–8.3) | 5.6 (2.8–8.9) | 4.5 (3.3–8.2) | 0.878 | |
| Systemic treatment discontinuation | 32 (26.2) | 23 (22.5) | 9 (45.0) | 0.037 | |
| Duration of treatment (mo) | 5.5 (3.2–11.1) | 5.4 (3.0–11.5) | 5.5 (4.1–9.4) | 0.742 | |
| PSA progression | 14 (11.5) | 8 (7.8) | 6 (30.0) | 0.011 | |
| PSA at PSA progression (ng/mL) | 25.1 (6.2–44.3) | 25.1 (6.8–50.9) | 29.3 (4.7–52.1) | >0.999 | |
| PSA progression duration (mo) | 10.2 (6.8–13.6) | 11.0 (4.5–13.8) | 10.2 (8.1–13.6) | 0.852 | |
| Radiographical progression | 12 (9.8) | 9 (8.8) | 3 (15.0) | 0.323 | |
| PSA at radiographical progression (ng/mL) | 8.9 (0.3–36.9) | 4.8 (0.2–13.3) | 36.9 (19.1–173.4) | 0.194 | |
| PSA at mCRPC progression (ng/mL) | 36.8 (6.9–145.1) | 14.5 (4.6–105.9) | 37.7 (26.6–167.9) | 0.343 | |
| mCRPC progression | 15 (12.3) | 11 (10.8) | 4 (20.0) | 0.258 | |
| mCRPC progression duration (mo) | 9.9 (5.7–12.2) | 8.4 (5.0–12.5) | 10.6 (9.0–11.4) | 0.571 | |
Values are presented as means±standard deviations, medians (interquartile ranges), or numbers (%), unless otherwise indicated.
mHSPC: metastatic hormone-sensitive prostate cancer, ADT: androgen-deprivation therapy, mCRPC: metastatic castration-resistant prostate cancer, LNM: lymph node metastasis, PSA: prostate-specific antigen.